We are now recruiting mentors for the sixth round of our Patient Group Mentoring Programme!
If you believe that you have something to offer to a rare disease patient group, whether that be advice on time management, ideas for patient involvement in research or simply a listening ear, we want to hear from you!
The deadline to apply is no later than midnight on 4th July - AKA this Sunday!
Our 2021-22 Programme will officially launch on 14th July.
Dr. Kazuo Takayama from the renowned Center for iPS Cell Research and application (CiRA) at Kyoto University (Japan) has given a unique insight into his pioneering research that has successfully modelled the SARS-CoV-2 life cycle in undifferentiated iPSCs - which were previously uninfectable.
The presentation which was given at ISSCR 2021, the leading professional organization for stem cell scientists, discussed how iPSCs and organoids can be used in COVID-19 drug discovery research.
22 June 2021
Taylor Wessing expands offering in China with the launch of Beijing Tailun IP Agency
Today we are announcing our expansion with the launch of an exclusive relationship with a specialist trade mark and IP agency in China.
With international law firms restricted from practicing Chinese law, a distinct legal entity has been established and permitted to provide a range of intellectual property related services by Chinese regulators.
LINK Medical and Ectin Research AB have signed an agreement appointing LINK Medical Research AB to run the Phase I/II clinical study of the treatment of metastatic bladder cancer patients with the drug candidate MFA-370. Ectin Research aims to submit its clinical trial application (CTA) to the Swedish Medical Products Agency, in collaboration with LINK Medical, followed by additional regulatory applications in two other countries.
Biocair recently opened a new office in Chicago, bringing the total number of US offices to nine. This addition to Biocair’s global network is just one of several investments made in the last year, all part of the company’s efforts to further expand its industry-leading supply chain solutions for life sciences.
The new facility will accommodate certified packaging and conditioning areas for a wide range of temperatures, including an advanced liquid nitrogen service station, as well as office space for Operations staff.
OXFORD, UK June 24th, 2021 – PrecisionLife Limited, a global healthcare combinatorial analytics company, announces that it has appointed Ray Pawlicki as Executive Chair to the Board of Directors.
Widely recognized as a leader in informatics across pharma and biotech, he will work closely with the PrecisionLife Board and CEO Steve Gardner to help steer the strategic growth of the company.
SOMERSET, N.J. – June 24, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has reached an agreement to acquire RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs).
Leiden, The Netherlands, 23 June 2021: CellPoint, a cell therapy company developing CAR-T therapeutics for use at the point-of-care, announces an agreement with Lonza’s Personalized Medicine Business Unit to employ Lonza’s Cocoon® Platform for clinical manufacturing of CellPoint’s CAR-T cell therapies at the point-of-care, more rapidly and at lower cost.
It has been more than two years that Data Protection Authorities of EU Member States (‘DPAs’) started to perform data protection audits. As part of their general task of monitoring compliance with the principles laid down by the General Data Protection Regulation (“GDPR”), each competent DPA may carry out inspections and impose sanctions. Whether you are data controller or processor, you may therefore be subject to an audit at any time. That is why all organizations need to be ready now.
• The partnership will support the progression of PY314, the first of Pionyr’s Myeloid TuningTM antibodies to enter the clinic
• Pionyr will use Abcam’s EPR20243 clone to evaluate TREM2 levels in tissue samples for potential future development as a CDx
• Abcam is Pionyr’s preferred partner for the long-term provision of anti-TREM2 antibody, suitable for use throughout the diagnostics development process